

MEDICAL FORGE LEIPZIG

Startups 2023/24



MEDICAL FORGE LEIPZIG by biosaxony
Deutscher Platz 5c
04103 Leipzig - Germany
Phone: +49 176 17965500

medicalforge@biosaxony.com
www.medicalforge.de



The Medical Forge Leipzig supports startups and innovative companies to bring their medical products faster to the German healthcare market. The customized 12 months accelerator program focuses on the specific needs of young health-tech companies. An extensive network including hospitals, health insurances and experienced industry partners provides invaluable insights and project opportunities. The inkind service bundle of the MEDICAL FORGE includes use of the coworking laboratories, 3D-printer, and electronic workshops as well as personal consulting and mentoring focusing on regulatory affairs for medical devices and therapies in the EU and Germany. Each selected team will receive a 25k Euro budget for their own specific needs (except for wages). The City of Leipzig offers up to 10k Euro on top if the startup registers a business entity there. The program is basically for free as it is funded by the German Federal Ministry for Economic Affairs and Climate Action. It is also equity free.

Glycanostics s.r.o.
Kudláková 7
841 01 Bratislava
Slovakia



eva.kovacova@glycanostics.com
www.glycanostics.com



Glycanostics® has developed an early-stage, highly accurate and unique cancer diagnostic test that analyses changes in glycan structures in glycoprotein biomarkers from blood serum. The technology was developed after more than 10 years of an intense research at the Slovak Academy of Sciences. Giasay® Prostate cancer test is being launched in Europe in Q2 2023, to be followed by Giasay® Breast cancer test at the end of 2023. Our granted patent covers also lung cancer, pancreatic cancer, ovarian, testicular, bladder, stomach, liver, colorectal and thyroid cancer (research work scheduled to start from 2024).

MicroX Labs Inc
565 Foxhall Ct
48304 Bloomfield Hills
Michigan | US



prakhar@microxlabs.com
www.microxlabs.com



MicroX Labs is an early-stage company developing a platform e-instrument “HomeCyte” for measurement of infection levels to risk stratify into mild, moderate and severe using set of disposable cartridges. Mild can stay at home, moderate visit hospital and severe need ventilator. The key blood tests which are currently performed are CBC (Complete blood cell count) and multi-plexed C-RP (C-reactive protein), PCT (Procalcitonin) and IL-6(Interleukin 6). Turn around time for CBC is 7 minutes and for immunoassays is ~30mins using finger stick blood. The amount of blood needed is ~50uL. Unmet need: Early and frequent clinical assessment of patients esp. immunocompromised and sepsis. Early and timely detection enables physicians to clinically risk stratify their patients into mild/moderate/ severe risk groups.

MUVON Therapeutics AG
c/o ETH Zürich
Weinbergstrasse 35 | WEH G-Stock
8092 Zürich | Schweiz

info@muvon-therapeutics.ch
www.muvon-therapeutics.com



MUVON
THERAPEUTICS

MUVON Therapeutics is a clinical stage Life Science Spin-off from the University of Zurich developing a novel therapy platform for the regeneration of skeletal muscle tissue based on autologous cells. We aim to provide safe, effective and affordable treatments to millions of patients suffering from seriously debilitating diseases by not only repairing damaged tissue but also increase the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

NeuroTrigger
Nirim 3
Tel Aviv

info@nt-med.com
www.nt-med.com



NEURO
TRIGGER

Facial paralysis impacts over 1,000,000 people worldwide each year, due to Bell's palsy, brain surgery, stroke, Parkinson's and other diseases. Eye closure is generally regarded as the top functional priority restoration in patients experiencing facial paralysis. The absence of blinking can lead to extremely painful corneal ulceration and severe dry eye, either can cause visual impairment or irreversible visual loss. Blinking is a mechanism that protects the eye and spreads tears over the cornea. The normal human eye blinks every 2-10 seconds, but with facial paralysis the ability to blink is usually impaired or absent. As a direct result, many patients suffer from dry eye, headaches, extreme light sensitivity and image quality degradation. Currently, there is no solution that restores blinking. All treatment options are inadequate since they intend to alleviate the symptoms but not to restore blinking. NeuroTrigger has developed and tested portable and user-friendly system that automatically stimulates artificial eyelid blinking.

SDS Optic Inc
Centrum ECOTECH-COMPLEX, Block A
ul. Głęboka 39
20-612 Lublin | Poland

office@sdsoptic.pl
www.sdsoptic.pl



SDS Optic Inc., HQ in Poland, publicly listed at Warsaw Stock Exchange, is first ever European based cutting-edge medical DeepTech connecting molecular biology with novel photonics technologies, chemistry & biomedical engineering to create solutions that can revolutionize healthcare worldwide, incl. first ever In Vivo Photonics Immunoassays platform - inPROBE® technology. SDS Optic discovers, develops and commercializes disruptive diagnostics and monitoring tools on a global scale, creating Lifesaving Innovations to help medical professionals in real-time diagnosis and monitoring of therapy increasing Patients' well-being. SDS Optic vision is to develop innovative cancer diagnostics & monitoring technologies which will help increase cancer survival rate by 30% by 2030.

Vésale Bioscience
Rue Louis Allaert, 9
5310 Noville-sur-Mehaigne
Belgium

info@phage.health
www.phage.health



Vesale Bioscience is a Belgium-based biotech company created in 2018 that is developing urgently needed therapeutics based on cutting-edge personalized phage therapy to fight antibacterial multi-resistant infections (AMR). Vesale Bioscience has developed the first on-site and fully automated susceptibility test that will recommend in 3,5 hours (instead of days/weeks) the optimal therapeutic phage(s) able to combat the patient's specific bacterial infection. Our personalised phage therapy model has already been used safely in more than 140 critically ill patients with a high rate of success. Our large phage library targets difficult-to-treat infections caused by *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli* and *Klebsiella pneumoniae*, bacteria that are responsible for 70% of AMR infections in EU & US. The team strongly believe that the sustainable phage therapy solutions will allow successful treatment of acute and chronic infections at the hospital and will improve patients' health and quality of life.

ZuriMED Technologies AG
Lengghalde 5
8008 Zürich | Schweiz

info@zurimed.com
www.zurimed.com



ZuriMED Technologies AG is an innovation-driven Swiss company based in Zurich that spun off in 2015 from the Laboratory for Orthopaedic Biomechanics (Department of Health Science and Technology at ETH Zurich and the Department of Orthopaedics at the University of Zurich). As an innovation engine with a dynamic management team and a Board of Directors of world-leading scientists and clinicians, ZuriMED's strength is to think outside the box and develop disruptive technologies that address unmet clinical needs.

MEDICAL FORGE
is a project of
[biosaxony Management GmbH](#)

Deutscher Platz 5c
04103 Leipzig
Germany

Phone: [+49 \(0\)351 7965 500](tel:+49(0)3517965500)
E-Mail: medicalforge@biosaxony.com

Supported by:



on the basis of a decision
by the German Bundestag